Skyrizi and Rinvoq Cannot Prevent Gut Cells from Dying; AbbVie Paid $100M for IBD Drug That Can
· techtimes.com · popularity 20/100 · 0 similar stories today
Read the original at techtimes.com →
Summary
AbbVie IBD drug deal: AbbVie paid $100 million upfront to license NXE0033744, an oral gut-restricted EP4 agonist from Nxera Pharma that targets a cell-death pathway Skyrizi and Rinvoq cannot block, in a deal worth up to $1.47 billion that could help the many IBD patients who still fail current therapies.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 3.